Alzheimer’s disease may begin its biological progression far earlier than symptoms suggest, with subtle shifts in brain and blood markers emerging decades in advance.
Scientists are uncovering a hidden phase of Alzheimer’s disease that may begin far earlier than most people realize. Long before memory loss becomes noticeable, subtle biological changes could already be underway — potentially starting in a person’s late 50s, according to new research from Mayo Clinic.
The study, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, tracks when key changes in the brain and blood begin to speed up over a person’s lifetime. The findings offer clues about the most effective timing for detection and prevention efforts.
Alzheimer’s disease is the most common type of dementia and affects about 6.9 million Americans age 65 and older. It is marked by abnormal buildup of proteins such as amyloid and tau, which can develop years before symptoms and are linked to cognitive decline. There is currently no cure.
Researchers at Mayo Clinic set out to determine when these biological shifts tend to occur. Identifying them earlier could give patients and families more time to plan, seek care, and take advantage of treatments that may slow disease progression.
The team analyzed data from 2,082 participants in the long-running Mayo Clinic Study of Aging. They examined multiple measures, including blood biomarkers, brain scans, and cognitive performance, to pinpoint when Alzheimer’s-related changes begin to accelerate.
“This population-based study provides an integrated view of age-related patterns across multiple Alzheimer’s biomarkers measured in blood and imaging, plus cognition,” says Mingzhao Hu, Ph.D., assistant professor in Mayo Clinic’s Department of Quantitative Health Sciences and first author of the study. “By estimating the ages when changes in health markers become more noticeable, the results show that many of these shifts tend to happen from late 50s through early 70s.”
Key Age Windows for Alzheimer’s Changes
“As Alzheimer’s research shifts toward prevention and earlier treatment, blood biomarkers will play a central role in identifying who is best suited for these therapies,” says Jonathan Graff-Radford, M.D., chair of Behavioral Neurology at Mayo Clinic and senior author of the study. “Knowing when these biomarkers start to change, and when they relate to cognitive impairment, helps point us to the ages when prevention screening could have the greatest impact.”
The researchers found that many Alzheimer’s-related markers begin to change more rapidly at certain ages.
Cognitive decline becomes more noticeable in the late 50s. In the early 60s, amyloid begins to build up more quickly in the brain — suggesting this period is a key stage when both mental performance and amyloid changes intensify. Amyloid-beta proteins cluster to form plaques, which are a defining feature of Alzheimer’s disease.
From the late 60s into the early 70s, signs of tau-related damage and overall neurodegeneration increase more sharply. Blood markers such as plasma GFAP, NfL, and p-tau show stronger changes between ages 68 and 72, along with greater brain shrinkage, especially in areas tied to memory.
Overall, the findings point to two main windows: one in the early 60s linked to cognition and amyloid PET imaging, and another from the late 60s to early 70s involving several blood markers and signs of neurodegeneration. These periods may represent important transition points in aging.
Moving Toward Earlier Detection and Prevention
Mapping the timeline of Alzheimer’s progression could help shift care toward earlier detection instead of focusing mainly on later stages. The researchers note that these findings reflect general population trends and are not meant to predict outcomes for individuals.
Still, the results provide a foundation for future work. Scientists plan to study whether these “breakpoints” can help forecast cognitive decline, confirm the patterns in more diverse groups, and follow individuals over time to better understand how the disease develops.
The study also highlights the growing importance of blood tests in Alzheimer’s research and care. These tests showed trends similar to brain imaging, suggesting they could help track disease-related changes and identify people at higher risk.
“When you think about population screening, the critical issue is timing,” says Dr. Graff-Radford. “You don’t want to start too early, before biomarkers change, and this work provides a way to begin addressing that,” adds Dr. Graff-Radford.
The findings may also guide screening strategies by identifying age ranges when blood tests are most useful. In addition, several blood marker patterns were consistent across two widely used lab platforms, indicating the results are not dependent on a single testing method.
Reference: “Breakpoints in Alzheimer’s disease biomarkers and cognition across the aging spectrum: The Mayo Clinic Study of Aging” by Mingzhao Hu, David S. Knopman, Terry Therneau, Angela J. Fought, Ekaterina Hofrenning, Val J. Lowe, Ronald C. Petersen, Alicia Algeciras-Schimnich, Clifford R. Jack, Nikki H. Stricker, Michelle M. Mielke, Prashanthi Vemuri and Jonathan Graff-Radford, 7 April 2026, Alzheimer’s & Dementia.
DOI: 10.1002/alz.71227
This research is part of a broader effort at Mayo Clinic known as the Precure initiative. It focuses on developing tools to help clinicians detect and address disease-related changes earlier, before symptoms appear or conditions become harder to treat.
Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.